argenx Details ALKIVIA Phase 3 Data at ACR; IMNM sBLA Planned by End-2026
ARGX sits 43% above its 52-week low of $661.85.
Summary
argenx presented full Phase 3 ALKIVIA data at ACR showing efgartigimod's first statistically significant win in IMNM, with an sBLA filing planned by end-2026. The dermatomyositis cohort showed a similar-sized benefit but did not reach statistical significance.
Key Events · Product Development and Regulatory · ARGX
-
ALKIVIA Hits Primary Endpoint
In the combined IMNM and DM population, mean TIS improvement at Week 52 was 15.4 points greater than placebo (48.0 vs 32.6, p=0.0011), and key secondary endpoints on response rate, time to response, muscle strength and disease activity were also met.
-
IMNM Subtype Shows Significant Benefit
IMNM patients had a 14.8-point greater TIS improvement versus placebo (45.1 vs 30.2, p=0.0048), plus a 43.5 percentage-point greater creatine kinase reduction and a 5.4-point MMT-8 strength gain — the first Phase 3 win in a subtype with no approved therapies.
-
Dermatomyositis Misses Significance
The DM cohort showed a clinically meaningful 14.5-point TIS improvement (51.5 vs 37.0) but p=0.1093 did not reach statistical significance in the smaller cohort; skin disease improved by 5.6 points on CDASI.
-
sBLA Filing Targeted by End-2026
argenx plans to submit a Supplemental BLA to the FDA for efgartigimod in IMNM by the end of 2026, supported by a Breakthrough Therapy Designation.
Analysis · ARGX · Life Sciences
ALKIVIA is the first Phase 3 study to show a statistically significant, clinically meaningful benefit in IMNM — an autoimmune myositis subtype with roughly 20,000 U.S. patients and no approved targeted therapy. In the combined IMNM/DM population, efgartigimod beat placebo by 15.4 TIS points at Week 52 (48.0 vs 32.6, p=0.0011), and the IMNM subgroup alone delivered a 14.8-point gap (45.1 vs 30.2, p=0.0048). The dermatomyositis cohort showed a similar 14.5-point effect but missed statistical significance (p=0.1093) in its smaller sample, so the near-term commercial case rests on IMNM. argenx says it will file an sBLA for IMNM by the end of 2026 under an existing Breakthrough Therapy Designation — that filing, and the FDA's acceptance of it, is the next hard checkpoint for adding a third indication to VYVGART. This is an incremental label-expansion story on top of a franchise already running at $1.7 billion in quarterly net sales, not a re-rating event.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $945.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.5B. The 52-week trading range was $661.85 to $1,072.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.